Similac Baby Formula Lawsuit

As of this October 11, 2026 review, Similac NEC litigation includes a reported partial resolution and case-specific appellate rulings—not one outcome for every family. Abbott's August 20 SEC filing disclosed approximately $670 million in aggregate agreements resolving Gill and claims for approximately 2,000 additional infants, without an admission of liability. That disclosure does not establish a universal claims program or an individual payout. Abbott's SEC filing.

For families reviewing a possible claim, three questions remain distinct: whether an agreement covers their claim, what the medical and feeding records establish, and which court and filing rules apply. A headline settlement amount cannot answer those questions.

Current Litigation Status and Partial Resolution

The Judicial Panel on Multidistrict Litigation (JPML) reported 844 pending actions in MDL 3026 as of October 1, 2026. This is a combined federal count involving Similac and Enfamil allegations, not an Abbott-only count, a count of infants or a total of state-court cases. JPML snapshot.

The JPML centralized the listed federal actions in the Northern District of Illinois before Judge Rebecca R. Pallmeyer on April 8, 2022, for coordinated pretrial proceedings. Coordination is not a finding of liability or automatic entitlement to a class-action payment. Initial transfer order.

Abbott's disclosed agreements and the JPML count measure different things at different dates. The roughly 2,000 additional infant claims in that resolution must not be added to or subtracted from the 844 combined federal actions to estimate unresolved Similac claims. Regarding the disclosure:

• No Universal Fund: This agreement is a partial compromise for specific cases and does not establish a universal signup program for all families.
• No Payout Benchmark: Dividing the aggregate amount by a headline claimant count does not establish what an individual receives.
• No Admission of Fault: The resolution was reached without an admission of liability by the manufacturer.

The reviewed disclosure does not supply a universal eligibility test, application deadline or per-family payment schedule. Ask qualified counsel whether any agreement or earlier release affects a specific claim; do not treat the reported amount as available compensation for every reader. Disclosure scope.

Key Appellate Rulings and Their Impact

Two recent Abbott-specific decisions illustrate different questions about evidence and forum. Neither resolves every NEC claim.

The Mar Affirmance (July 24, 2026)

The Seventh Circuit affirmed judgment for Abbott in Mar. Its decision turned on warning causation: the plaintiff had not shown that the proposed warning would have prevented the death on that record. The court expressly declined to reach Abbott's broader formula but-for causation argument. That is not a brand-wide medical exoneration or proof that other claims will fail. Mar opinion, pages 2 and 11–12.

The Rodriguez Rule 23 Order (September 11, 2026)

Illinois's First District Appellate Court reversed denial of Abbott's forum non conveniens motion and remanded for dismissal conditioned on timely filing in Florida, Abbott accepting service and waiving any available statute-of-limitations defense. The court considered the case's connections to Florida and access to treating-provider evidence. This was a forum ruling, not a decision that Similac cannot cause NEC. The Rule 23 order has limited precedential use; its refiling conditions are not a general deadline extension for other families. Rodriguez order, paragraphs 26–28.

Allegations and Medical Context

The lawsuits involve allegations of inadequate warnings, design defects and misrepresentation concerning cow's-milk-based products used for premature infants. Allegations are not findings that Abbott is liable in every case. The Rodriguez order describes those theories in that family's complaint. Complaint context in the court order.

Medical evidence is a separate question from litigation outcomes. NICHD's February 7, 2024 summary describes a randomized trial of infants born before 29 weeks or weighing less than 1,000 grams. Infants receiving donor milk had lower NEC rates than those receiving formula in that studied population. NICHD trial summary.

That comparison does not establish that every Similac product causes NEC or determine an individual child's cause. Feeding and treatment decisions belong with the child's neonatal intensive care unit (NICU) team. A lawsuit webpage should not be used to change prescribed feeds or blame a family when maternal or donor milk was unavailable.

Product Specificity and Evidence

The Mar opinion describes Similac Special Care 24 exposure in that individual case. Mar product history. The Rodriguez order concerns an alleged Similac fortifier exposure. Rodriguez background. These examples do not form an eligibility list for every Similac product.

For a case-specific assessment, identify the actual manufacturer, formulation, administration dates and diagnosis chronology. A retail purchase alone does not establish that the product was administered in a NICU or caused an injury. The checklist below is practical preparation, not a legal test guaranteeing eligibility.

Essential Documentation for Case Assessment

Filing a Claim and Legal Timelines

Do not rely on a generic two- or three-year filing period. Qualified counsel must assess applicable law, claim type, relevant dates, earlier proceedings and any rules concerning the child's age. This article calculates no deadline and does not promise that a child-related rule extends one. Rodriguez's conditional waiver concerned that case, not all families. Obtain individualized advice promptly rather than assuming either that time has expired or that an extension applies.

Historical Product Recalls

The following historical recalls concern different product-safety issues from the NEC allegations. Their dates, formulations and reasons should not be collapsed into one event.

February 2022 powdered-formula recall

FDA records describe recalls of certain Similac, Alimentum and EleCare powdered formulas made at Abbott's Sturgis facility amid contamination concerns. This was a limited product/lot investigation, not a conclusion that all Similac causes NEC. FDA investigation.

October 14, 2022 ready-to-feed recall

The FDA-posted Abbott announcement concerned certain 2-fluid-ounce ready-to-feed lots because incomplete bottle-cap seals could allow spoilage. It was distinct from the powder contamination recall. FDA-posted recall announcement.

A historical recall alone does not establish individual NEC causation or lawsuit eligibility. Consult the exact FDA notice for product and date scope, and ask a clinician about feeding concerns; do not treat an old notice as current instructions for every brand product.

Next Steps for Affected Families

If your child was diagnosed with NEC following the use of Similac in a NICU setting:

• Prioritize Medical Care: Ensure all ongoing health needs are managed by qualified pediatric specialists.
• Request Records: Secure copies of the NICU feeding logs and the formal pathology or surgical reports confirming the NEC diagnosis.
• Seek Legal Assessment: Consult with an attorney experienced in complex medical product liability to review the specific timeline and evidence of your case.

This information is for general educational purposes and does not constitute medical or legal advice. Legal deadlines are strict, and families should seek professional counsel to protect their rights.

Legal.com Liability Disclaimer

All content published by Legal.com is provided for general informational purposes only. It is not legal advice, does not constitute a legal opinion, and should not be relied upon as a substitute for consultation with a qualified attorney. No attorney-client relationship is created by reading this article, using Legal.com templates, or contacting Legal.com. Legal.com disclaims all liability for actions taken or not taken based on this publication.